Is it working? Are your symptoms improving, staying the same, or getting worse? You may be asked to fill out a couple of ...

With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...

It can transition into chronic urticaria for up to 8% of the population. Hives tend to go away without treatment, but self-care strategies like taking a cooling bath can help manage discomfort. Some ...

In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Hives and eczema both involve itchy skin rashes and are related to allergies. While they may share some similarities, these two conditions are distinct in their symptoms, underlying causes, and ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, Evommune, and others are evaluating new urticaria drugs to improve the treatment landscape. Promising pipeline urticaria ...

Chronic spontaneous urticaria is an inflammatory skin disease that causes hives that last for at least six weeks. Derms ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...